Prefilled Syringes Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global prefilled syringes market growth forecasted to transform from USD 7.1 billion in 2024 to USD 13.1 billion in 2030, driven by a CAGR of 10.8%. The market for prefilled syringes is expanding significantly as a result of rising chronic illness rates that necessitate frequent treatment, and growing demand for effective and practical drug delivery methods. Healthcare settings are adopting these syringes because of their benefits, which include decreased drug errors, exact dosing, and improved patient safety. Further driving the market expansion is the increased emphasis on self-administration, as well as regulatory support for safer injection methods.

A prefilled syringe is a convenient medical device for delivering parenteral medications, offering a premeasured single-dose. This syringe benefits manufacturers by minimizing drug waste and extending product lifespan, while also making self-administration easier for patients at home or outside of hospital settings. Drugs commonly packaged in prefilled syringes include biologics, vaccines, blood stimulants, therapeutic proteins, erythropoietin products, and interferons.

Prefilled Syringes Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Prefilled Syringes Market Dynamics

Driver: Increasing prevalence of chronic diseases

The prefilled syringes market growth is largely being driven by the rising prevalence of chronic diseases like diabetes, cardiovascular disease, and autoimmune disorders. Prefilled syringes provide a practical, safe, and effective alternative for patients and healthcare professionals alike, as these disorders frequently necessitate the exact and regular administration of drugs. They raise patient compliance, lower the possibility of dosage errors, and improve the standard of treatment. Prefilled syringes demand is further fueled by the growing trends in self-administration, especially with regard to biologics and biosimilars, which is driving the market's growth.

Restraint: Impact of product recalls

Product recalls impede the prefilled syringe market's growth by eroding consumer confidence in these medical products. Manufacturers suffer significant financial losses as a result of recalls, which are frequently caused by contamination, or safety hazards. These losses also stem from potential legal obligations. They may also interfere with supply chains, leading to delays and shortages that impact patients and healthcare providers. All of these factors impede the market growth and impact the general uptake of prefilled syringes.

Opportunity: Increasing demand for biologics and biosimilars

The market for pre-filled syringes has a significant opportunity due to the growing need for biologics and biosimilars. A growing number of people are using biologics, complex drugs made from living things, and biosimilars to treat chronic illnesses. Pre-filled syringes provide a practical and accurate option because these therapies need precise and dependable delivery techniques to guarantee efficacy and patient safety. The market for pre-filled syringes is expected to rise significantly due to their capacity to lower dose errors, increase patient compliance, and improve overall healthcare outcomes. These benefits perfectly complement the growing usage of biologics and biosimilars.

Challenge: Alternative drug delivery methods

In the pre-filled syringe market, alternative drug administration technologies pose a serious threat by providing several options that may be seen as more practical or efficient for particular medical conditions. Various technologies like as autoinjectros, pen injectors, needle-free injectors, transdermal patches, and oral medication formulations offer various benefits like pain reduction, user-friendliness, and increased patient adherence. These substitutes may lessen the need for pre-filled syringes since patients and medical professionals may favor techniques that make injections less uncomfortable or simpler to use. As a result, in order for the pre-filled syringe business to be competitive, it must constantly innovate and highlight its advantages.

Prefilled Syringes Market Ecosystem

The prefilled syringe market ecosystem incorporates a number of players, including patients, healthcare professionals, regulatory agencies, manufacturers of medical devices, and pharmaceutical firms. Pharmaceutical businesses create and supply injectable drugs, which are subsequently filled by specialist manufacturers into syringes. These producers prioritize maintaining accuracy, sterility, and safety; to reduce the possibility of contamination and needlestick accidents, they frequently use cutting-edge technologies like needle safety devices. The main consumers of these devices are healthcare professionals, such as clinics and hospitals, who depend on their dependability and simplicity to improve patient care.

Particularly for chronic illnesses needing frequent injections, patients benefit from the pre-filled syringes' convenience of use and decreased risk of dose errors. Self-administration trends, which are fueled by patient preferences for at-home care and advancements in user-friendly design, also have an impact on the market. Advancements are driven by collaborations and partnerships across various entities, guaranteeing that the ecosystem adapts to meet the increasing needs for patient-centric solutions, safety, and efficiency.

By type, conventional prefilled syringes segment holds largest share in the prefilled syringes industry.

The prefilled syringes market, by type is dominated by the conventional prefilled syringes. These prefilled syringes are found in a wide range of medical settings such as clinics, hospitals, and home care settings. Their extensive use guarantees a consistent and high demand. These syringes are an appealing choice for healthcare providers looking to control expenses while preserving high-quality patient care because they are typically less expensive than more sophisticated or specialized needles. Furthermore, because conventional prefilled syringes are more convenient and require less preparation than traditional vial-and-syringe procedures, they typically improve patient compliance with treatment regimens. Conventional prefilled syringes have a large market penetration because of their extended shelf life and hence contributes to their dominant market share.

By material, glasses prefilled syringes segment is expected to have the largest market share in the prefilled syringes industry.

The dominance of the glass prefilled syringes segment can be attributed to several factor such as there is a lower possibility of medication interactions with these syringes, drug efficacy and integrity are ensured, which is especially important for expensive and sensitive biologics. Glass syringes are becoming more popular due to technological developments including better safety features and decreased breakage. Owing to this, pharmaceutical companies are favoring glass prefilled syringes more when it comes to administering injectable medicines, which has led to their significant market share.

By design, the single-chamber prefilled syringe segment is expected to dominate the prefilled syringes industry from 2024 to 2029.

The single-chamber prefilled syringe dominates the prefilled syringes market due its convenient features. The single-chamber prefilled syringe optimizes dosing accuracy, decreases preparation time, and minimizes contamination by combining the medicine and delivery mechanism into a single chamber. Its ease of use and effectiveness make it a desirable alternative for patients and healthcare providers alike, leading to higher acceptance and market share.

By application, cancer segment is expected to have the largest market share in the prefilled syringes industry.

In the prefilled syringes market, the cancer segment is holds the largest market share due to the rising incidence of cancer and the growing need for accurate and effective drug delivery methods for cancer treatments. Pre-filled syringes include benefits like lower dosing mistake risk, better patient compliance, and convenience, all of which are crucial for cancer therapies, which sometimes call for frequent and precise medicine administration. In addition, biologic therapies and chemotherapy are frequently employed in cancer therapy. Injectable formulations are used to give several of these therapies. Prefilled syringes provide a convenient option that minimizes dosage errors, saves preparation time, and improves patient safety. Thus, the use of prefilled syringes will grow as cancer treatments continue to advance and the need for effective drug delivery systems grows.

North America accounted for the largest market share of the global prefilled syringes industry, by region in the forecast period.

The pre-filled syringe market is anticipated to be dominated by the North American region due to a number of factors, including an advanced healthcare infrastructure, a high prevalence of chronic diseases, and a focus on patient safety and technological innovation. Its dominant position in the market is also a result of the region's well-established pharmaceutical industry and rising demand for practical and precise drug delivery solutions. Furthermore, continued R&D expenditures and favorable regulatory environments in North America contribute to the expansion and use of pre-filled syringes.

To know about the assumptions considered for the study, download the pdf brochure

The key players in the prefilled syringes market include BD (US), Gerresheimer AG (Germany), SCHOTT (Germany), and West Pharmaceutical Services, Inc. (US), AptarGroup Inc. (US), Nipro (Japan), Baxter (US), Owen Mumford Ltd. (UK), Weigao Meidcal international Co., Ltd. (China), Credence MedSystems, Inc. (US), Novartis AG (Switzerland), Stevanato Group (Italy), Polymedicure (India), MedXL (Canada), Sharps Technology, Inc. (US), Fresenius Kabi (US), DBM S.R.L. (Italy), Taisei Kako Co.,Ltd (Japan), Shandong Province Medicinal Glass Co., Ltd. (China), SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD (Japan), J.O. PHARMA CO., LTD. (Japan), BMIKOREA (Korea), B. Braun SE (Germany), and Al Shifa Medical Products Co. (Saudi Arabia).

Prefilled Syringes Market Report Scope

The research report categorizes prefilled syringes market to forecast revenue and analyze trends in each of the following submarkets:

By Type

• Conventional Prefilled Syringes
  • Disposable Prefilled Syringes
  • Reusable Prefilled Syringes
• Safety Prefilled Syringes

By Material

• Glass Prefilled Syringes
• Plastic Prefilled Syringes

By Design

• Single-Chamber Prefilled Syringes
• Dual-Chamber Prefilled Syringes
• Customized Prefilled Syringes

By Application

• Diabetes
• Rheumatoid Arthritis
• Anaphylaxis
• Cancer
• Thrombosis
• Ophthalmology
• Others

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
• GCC Countries

Recent Developments of Prefilled Syringes Market

• In April 2024, Baxter announced the expansion of its Pharmaceuticals portfolio with the launch of five new injectable products in the US. These launches focus on addressing unmet patient needs in key therapeutic areas, such as anti-infective and anti-hypotensive medications.
• In June 2024, SCHOTT Pharma (Germany) constructed a new production facility dedicated to prefillable glass syringes (PFS) at its location in Lukácsháza, Hungary. This strategic step demonstrated the company's proactive approach in offering advanced solutions for the storage of biologics, vaccines, and the newest generation of mRNA-based medications.
• In May 2023, Gerresheimer Glass GmbH, a subsidiary of Gerresheimer AG (Germany), signed a purchase agreement to acquire Bormioli Pharma Group. This acquisition strengthens Gerresheimer’s European presence and enhances its position in the pharmaceutical and biotech packaging market.
• In May 2023, Baxter(US) signed a final agreement to sell its BioPharma Solutions (BPS) division to Advent International and Warburg Pincus, both renowned investment firms. This deal signifies the divestment of Baxter's contract development and manufacturing arm.
• In September 2022, BD (US) launched a next-generation glass prefillable syringe (PFS) that sets a new benchmark for vaccine performance by meeting tighter processability, cosmetics, contamination, and integrity requirements. Leading pharmaceutical companies collaborated to design the innovative BD Effivax Glass Prefillable Syringe to address the growing demand for vaccine manufacturing.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst